Barakaldo

• Assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke. Recruiting
  2024-519551-29-00 5 2025-08-21 Acute cerebral ischemic stroke
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 7 2025-08-11 Propionic Acidemia
• A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting
  2023-504478-39-00 5 2025-05-23 Squamous cell carcinoma of head and neck
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso … Recruiting
  2024-515706-77-00 5 2025-05-08 Moderate to Severe Plaque Psoriasis
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 5 2024-07-15 Urothelial Carcinoma
• Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized … Recruiting
  2023-508441-41-00 6 2024-07-08 Bacteriemia producida por P. aeruginosa.
• A Multicentre Study to Evaluate the Safety and Efficacy of the Eye Implant ILUVIEN® in Children with non-infectious uveitis affecting the po … Recruiting
  2023-509469-19-00 11 2024-04-17 Non-Infectious Uveitis affecting the posterior segment
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-505121-14-00 5 2024-01-18 Moderate to Severe Plaque Psoriasis
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting
  2023-505140-19-00 5 2023-07-31 Childhood Idiopathic Nephrotic Syndrome
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non-muscle invasiv … Recruiting
  2024-520006-19-00 6 2021-12-15 Non-muscle invasive bladder cancer
• Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting
  2024-511686-11-00 5 2021-10-05 Multiple Sclerosis in pediatric patients
• A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos … Recruiting
  2022-502784-37-00 4 2019-09-03 Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 ye
• A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting
  2025-522979-29-00 5 2026-04-30 Acute myeloid leukemia
• SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study Recruiting
  2025-521560-36-00 4 2026-04-22 Type 1 Diabetes
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and be … Recruiting
  2025-521459-22-00 4 2026-03-27 Patients with resectable hepatocellular carcinoma (amenable R0 resecti
• An Open-Label Extension, Multi-Centered, Phase 2 Trial of TEV-56286 (Emrusolmin) for Multiple System Atrophy Recruiting
  2025-521642-14-00 4 2026-03-05 Multiple System Atrophy
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• RANDOMISED CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF PLATELET-RICH PLASMA (PRP) INFILTRATION COMBINED WITH PHYSICAL EXERCISE IN CH … Recruiting
  2025-522700-24-00 5 2026-01-13 CHRONIC OMALGIA
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases

Showing 25–48 of 197 trials